SK Biopharmaceuticals Co., Ltd.

326030 · KOSPI

Public Market Listing

326030KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for SK Biopharmaceuticals Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Cenobamate(Xcopri)
Approved
Sodium channels + GABA-A receptorsSmall molecule
Epilepsy
Focal Onset Seizures
Solriamfetol(Sunosi)
Approved
Dopamine/norepinephrine transporterSmall molecule
Major Depressive DisorderNarcolepsyAttention Deficit Hyperactivity Disorder
Phase 3
Voltage-gated sodium channelSmall molecule
Epilepsy

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Solriamfetol · SunosiPhase 3Binge-Eating Disorder
Est. primary completion 2026-12 · NCT06413433 · CT.gov ↗
What to watch
Solriamfetol · SunosiPhase 3Excessive Sleepiness, Shift-work Disorder
Est. primary completion 2026-12 · NCT06568367 · CT.gov ↗
What to watch
2027 (5)
January 2027 (2)
Cenobamate · XcopriPhase 2Epilepsies, Partial
Est. primary completion 2027-01-31 · NCT06590896 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3Epilepsy, Generalized
Est. primary completion 2027-01-31 · NCT06579573 · CT.gov ↗
What to watch
February 2027 (1)
CarisbamatePhase 3Seizures, Lennox Gastaut Syndrome
Est. primary completion 2027-02 · NCT05219617 · CT.gov ↗
What to watch
December 2027 (2)
Solriamfetol · SunosiPhase 3Binge-Eating Disorder
Est. primary completion 2027-12 · NCT06878976 · CT.gov ↗
What to watch
Est. primary completion 2027-12 · NCT07773883 · CT.gov ↗
What to watch
2028 (4)
March 2028 (1)
Cenobamate · XcopriPhase 3Partial Epilepsy
Est. primary completion 2028-03-30 · NCT07594158 · CT.gov ↗
What to watch
June 2028 (2)
Est. primary completion 2028-06-30 · NCT07717879 · CT.gov ↗
What to watch
Est. primary completion 2028-06-30 · NCT07717892 · CT.gov ↗
What to watch
December 2028 (1)
Solriamfetol · SunosiPhase 3Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Est. primary completion 2028-12 · NCT07484217 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

31 January 2027FDA action dateCenobamatePDUFA date set for cenobamate oral suspension
US, FDA · Source ↗

Recent

4 November 2026Filing submittedCenobamateSK Biopharmaceuticals submits sNDA for cenobamate in PGTC seizures and pediatric focal-onset seizures
US, FDA · SK Biopharmaceuticals · Source ↗
15 June 2026Filing acceptedCenobamateFDA accepts NDA for cenobamate oral suspension
US, FDA · Source ↗
25 March 2025Topline resultSolriamfetolFOCUS Phase 3 of solriamfetol in adult ADHD (NCT05972044) met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗

Financial reports

No financial reports recorded.